Compressed sensing (CS) MP2RAGE versus standard MPRAGE: A comparison of derived brain volume measurements

Ferraro, Pilar M.; Gualco, Lorenzo; Costagli, Mauro; Schiavi, Simona; Ponzano, Marta; Signori, Alessio; Massa, Federico; Pardini, Matteo; Castellan, Lucio; Levréro, Florence; Zacà, Domenico; Piredda, Gian Franco; Hilbert, Tom; Kober, Tobias; Roccatagliata, Luca

doi:10.1016/j.ejmp.2022.10.023

Cited by 6 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, compared with conventional sequences, the use of CS may be restricted as it usually requires more computational power 20 , 34 . Recently, CS-MP2RAGE was introduced and tested in evaluating brain volume as an alternative of standard MPRAGE showing same quality and higher contrast than the standard MPRAGE with almost half of the scan time 35 , 36 . We are expecting to apply CS-MP2RAGE and validate the sequence in diagnosing intracranial lesions with future studies.…”

Section: Discussionmentioning

confidence: 99%

Clinical feasibility of CS-VIBE accelerates MRI techniques in diagnosing intracranial metastasis

Park

Yim

Chung³

2023

Sci Rep

View full text Add to dashboard Cite

Our objective was to evaluate and compare the diagnostic performance of post-contrast 3D compressed-sensing volume-interpolated breath-hold examination (CS-VIBE) and 3D T1 magnetization-prepared rapid-acquisition gradient-echo (MPRAGE) in detecting intracranial metastasis. Additionally, we analyzed and compared the image quality between the two. We enrolled 164 cancer patients who underwent contrast-enhanced brain MRI. Two neuroradiologists independently reviewed all the images. The signal-to-noise ratio (SNR), contrast-to noise ratio (CNR) were compared between two sequences. For patients with intracranial metastasis, we measured enhancement degree and CNRlesion/parenchyma of the lesion. The overall image quality, motion artifact, gray-white matter discrimination and enhancing lesion conspicuity were analyzed. Both MPRAGE and CS-VIBE showed similar performance in diagnosing intracranial metastasis. Overall image quality of CS-VIBE was better with less motion artifact; however conventional MPRAGE was superior in enhancing lesion conspicuity. Overall, the SNR and CNR of conventional MPRAGE were higher than those of CS-VIBE. For 30 enhancing intracranial metastatic lesions, MPRAGE showed a lower CNR (p = 0.02) and contrast ratio (p = 0.03). MPRAGE and CS-VIBE were preferred in 11.6 and 13.4% of cases, respectively. In comparison with conventional MPRAGE, CS-VIBE achieved comparable image quality and visualization, with the scan time being half of that of MPRAGE.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical feasibility of CS-VIBE accelerates MRI techniques in diagnosing intracranial metastasis

Park

Yim

Chung³

2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…internal capsule, thalamic radiations, and internal medullary lamina), could bias the segmentation of these nuclei, hence subsequent volume correlations. Alonso et al (2021) andFerraro et al (2022) found evidence that the volume of the whole thalamus can change significantly in relation to the choice of MPRAGE variants. These authors included standard MPRAGE in their comparisons with a single other CS-accelerated MPRAGE variant, and did not investigate sequence effects in thalamic nuclei exclusively, by reason of their main interest in other cortical and subcortical structures.…”

Section: Volume Correlationsmentioning

confidence: 99%

“…CS has recently been applied to several T1w sequences, such as the standard vendor-provided magnetization-prepared rapid gradient echo (MPRAGE; Mugler & Brookeman, 1990) and its variant MP2RAGE (Marques et al, 2010). In general, reports are of comparable quality and volumetry to parent non CSaccelerated sequences in a number of brain structures (Mussard et al, 2018;Mair et al, 2019Mair et al, , 2020Mönch et al, 2020;Dieckmeyer et al, 2021;Ferraro et al, 2022), with biases at higher accelerations. So far, the effect of CS acceleration of various MPRAGE sequence variants has not yet been investigated on the volumetry of thalamic nuclei specifically.…”

Section: Introductionmentioning

confidence: 99%

Advancing Thalamic Nuclei Segmentation: The Impact of Compressed Sensing and FastSurfer on MRI Processing

Hübner,

Tambalo,

Novello

et al. 2024

Preprint

Self Cite

View full text Add to dashboard Cite

The thalamus is a collection of gray matter nuclei that play a crucial role in sensorimotor processing and modulation of cortical activity. Characterizing thalamic nuclei non-invasively with structural MRI is particularly relevant for patient populations with Parkinson’s disease, epilepsy, dementia, and schizophrenia. However, severe head motion in these populations poses a significant challenge for in vivo mapping of thalamic nuclei. Recent advancements have leveraged the compressed sensing (CS) framework to accelerate structural MRI acquisition times in MPRAGE sequence variants, while fast segmentation tools like FastSurfer have reduced processing times in neuroimaging research.In this study, we evaluated thalamic nuclei segmentations derived from six different MPRAGE variants with varying degrees of CS acceleration (from about 9 to about 1 minute acquisitions), using both FreeSurfer and FastSurfer for segmentation. Our findings show minimal sequence effects with no systematic bias, and low volume variability across sequences for the whole thalamus and major thalamic nuclei. Notably, CS-accelerated sequences produced less variable volumes compared to non-CS sequences. Additionally, segmentations of thalamic nuclei by FreeSurfer and FastSurfer were highly comparable.We provide first evidence supporting that a good segmentation quality of thalamic nuclei with compressed sensing T1-weighted image acceleration in a clinical 3T MRI system is possible. Our findings encourage future applications of fast T1-weighted MRI to study deep gray matter. CS-accelerated sequences and rapid segmentation methods are promising tools for future studies aiming to characterize thalamic nuclei in vivo at 3T in both healthy individuals and clinical populations.

show abstract

Alzheimer's Disease Clinical Trials: What Have We Learned From Magnetic Resonance Imaging

By,

Kahl,

Cogswell

2024

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Alzheimer's disease (AD) is the leading cause of cognitive impairment and dementia worldwide with rising prevalence, incidence and mortality. Despite many decades of research, there remains an unmet need for disease‐modifying treatment that can significantly alter the progression of disease. Recently, with United States Food and Drug Administration (FDA) drug approvals, there have been tremendous advances in this area, with agents demonstrating effects on cognition and biomarkers. Magnetic resonance imaging (MRI) plays an instrumental role in these trials. This review article aims to outline how MRI is used for screening eligibility, monitoring safety and measuring efficacy in clinical trials, leaning on the landscape of past and recent AD clinical trials that have used MRI as examples; further, insight on promising MRI biomarkers for future trials is provided.Level of Evidence1.Technical EfficacyStage 4.

show abstract

Compressed sensing (CS) MP2RAGE versus standard MPRAGE: A comparison of derived brain volume measurements

Cited by 6 publications

References 30 publications

Clinical feasibility of CS-VIBE accelerates MRI techniques in diagnosing intracranial metastasis

Clinical feasibility of CS-VIBE accelerates MRI techniques in diagnosing intracranial metastasis

Advancing Thalamic Nuclei Segmentation: The Impact of Compressed Sensing and FastSurfer on MRI Processing

Alzheimer's Disease Clinical Trials: What Have We Learned From Magnetic Resonance Imaging

Contact Info

Product

Resources

About